Bayer’s big kidney disease readout approaches
Bayer has invested heavily in finerenone in kidney disease, but the window of opportunity has narrowed. Data will soon show whether it has shut completely.
Amarin falls at obvious hurdle
Amarin’s loss of a crucial patent lawsuit shows that potential buyers were right to be wary of the Vascepa opportunity.
ACC 2020 – Merck and Bayer face a fight with new heart failure pill
Merck & Co and Bayer’s vericiguat was deemed another “win” for heart failure at a medical conference this weekend. But widespread use looks unlikely.
Upcoming events – Milestone's milestone and Transmedics' panel
Soon Milestone will report pivotal data with etripamil, an intranasal heart arrhythmia therapy, and an FDA adcom approaches for Transmedics' heart preservation…
Esperion shifts to show not tell
After spending years insisting that its cholesterol-lowering medicine has a place between statins and PCSK9 inhibitors, Esperion must now prove it.
A listless quarter for Medtronic
Medtronic has lined up a whole pipeline of new devices – and it will need them.
Biopharma’s big bet on cancer is laid bare
Drug developers have directed almost half of their dealmaking firepower at oncology projects over the past five years, with cardiovascular a distant second.
ACC preview: a veri important test for Merck and Bayer
Heart failure data must repay Bayer and Merck & Co for taking a chance on vericiguat, and a hit for Medtronic’s renal denervation system could erase the shame of its…
The cost to Astrazeneca of building Brilinta
Thales, the final Brilinta outcome trial in Astrazeneca’s huge Parthenon programme, has hit – but the UK group’s vast investment in its blood thinner has yet to pay off.
